Depression treatment has largely relied on medications, but they can take weeks to work, if they work at all. Now, a study from Sweden is offering a glimpse into something radically different: meaningful relief from depression after just a single dose of psilocybin, the psychedelic compound found in so-called “magic mushrooms.”

The findings suggest that psilocybin-assisted therapy may someday become an important option for people struggling with major depression, particularly when rapid symptom relief is urgently needed.

Eight days after treatment, depression scores in the psilocybin group had dropped by an average of 9.7 points, compared with a drop of just 2.4 points in the placebo group.

Researchers at Karolinska Institutet in Sweden tested psilocybin treatment in people with common forms of recurrent depression, not just treatment-resistant depression or cancer-related distress, which have been the focus of earlier psychedelic studies. The study was a randomized, double-blind clinical trial and enrolled 35 adults between the ages of 20 and 65 who had moderate to severe recurrent depression.

Participants needed a score of at least 22 on a widely used tool for measuring depressive symptoms, the Montgomery-Asberg Depression Rating Scale (MADRS), to qualify. They were randomly assigned to receive either a single 25-milligram dose of psilocybin or an active placebo consisting of niacin, a vitamin known to cause physical sensations such as skin flushing.

Using an active placebo helped researchers maintain the “blind” nature of the study since psychedelic drugs often produce unmistakable effects.

Both groups received extensive support before, during and after treatment. On dosing day, participants reclined comfortably, wearing eye masks and headphones while listening to music designed to encourage inward reflection. Therapists remained present throughout the experience.

Eight days after treatment, depression scores in the psilocybin group had dropped by an average of 9.7 points, compared with a drop of just 2.4 points in the placebo group. Researchers described the 7.3+ point difference as both statistically significant and clinically meaningful. Some participants reported feeling better within just two days.

After six weeks, over half of the participants who received psilocybin were considered in remission, meaning their depressive symptoms had largely resolved. Only six percent of those receiving placebo achieved remission during that same period.

The finding could have major implications for mental health care. “Our results suggest that psilocybin can provide rapid, clinically meaningful improvement in depression and may serve as an alternative to standard treatment when fast symptom medication is important,” lead author Hampus Yngwe, MD, MSc, a consultant psychiatrist and PhD student in the Department of Clinical Neuroscience at the Karolinska Institutet, said in a press release.

Yngwe also urged caution, noting that important questions remain unanswered: “However, the long-term effects are uncertain. Repeated treatments may be needed to prevent relapse. This needs to be investigated in larger studies.”

Psychedelic therapy is not without its risks. Some patients may need extra support. Most side effects in the study were mild or temporary, but two participants experienced severe anxiety requiring medical attention.

Some participants reported feeling better within just two days, but two participants experienced severe anxiety requiring medical attention.

The researchers also acknowledged one of the major challenges in psychedelic science is maintaining proper blinding. Because psilocybin produces such noticeable psychological effects, nearly all participants correctly guessed whether they had received the drug or the placebo, despite the administration of niacin, potentially influencing the results through expectation alone.

Even so, scientists remain intrigued by what may be happening biologically inside the brain. Emerging evidence suggests psilocybin may help promote “Synaptic growth,” strengthening connection between nerve cells that are often impaired in depression.

A second 2026 study extended those findings into another deeply vulnerable group: people with chronic thoughts of suicide. In that open-label trial, a single dose of psilocybin combined with psychological support produced rapid and sustained reductions in suicidal ideation lasting up to 12 weeks. Researchers described the results as among the largest effect sizes ever reported for psychiatric treatment targeting suicidality.

Together the studies suggest that psychedelic-assisted therapy may be entering a new phase — one moving from cultural controversy into serious clinical science.

As of yet, psylocibin is not an approved treatment for depression outside research settings. But for millions living under the heavy weight of depression, the idea that relief could begin in days, instead of weeks, may represent something many patients have not felt in a very long time — a faster way out of their sadness.

The study is published in JAMA Network Open.